Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

por Ansstas, George, Tran, David D.
Publicado 2016

Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombinati...

por Khaddour, Karam, Ansstas, Michael, Ansstas, George
Publicado 2021

The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions

por Khaddour, Karam, Johanns, Tanner M., Ansstas, George
Publicado 2020

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma

por Khaddour, Karam, Johanns, Tanner M, Ansstas, George
Publicado 2021

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

por Khaddour, Karam, Zhou, Alice, Butt, Omar, Huang, Jiayi, Ansstas, George
Publicado 2023

PARP inhibition and immunotherapy: a promising duo in fighting cancer

por Phillipps, Jordan, Zhou, Alice Y., Butt, Omar H., Ansstas, George
Publicado 2023

Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa

por Khaddour, Karam, Gorell, Emily S., Dehdashti, Farrokh, Tang, Jean Y., Ansstas, George
Publicado 2020

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation

por Khaddour, Karam, Fields, Ryan C., Ansstas, Michael, Rosman, Ilana S., Ansstas, George
Publicado 2020

Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors...

por Khaddour, Karam, Khanna, Sangeeta, Ansstas, Michael, Jakhar, Ishaan, Dahiya, Sonika, Council, Laurin, Ansstas, George
Publicado 2021

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches

por Khaddour, Karam, Maahs, Lucas, Avila-Rodriguez, Ana Maria, Maamar, Yazan, Samaan, Sami, Ansstas, George
Publicado 2021

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios

por Khaddour, Karam, Zhou, Alice, Butt, Omar H., Budde, Griffin, Malashevich, Allyson Koyen, Ansstas, George
Publicado 2022

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome

por Khaddour, Karam, Musiek, Amy, Cornelius, Lynn A., Dehdashti, Farrokh, Westervelt, Peter, Fields, Ryan, Ansstas, George
Publicado 2019

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection

por Shmuylovich, Leonid, McEvoy, Aubriana M., Fields, Ryan C., Hernandez-Aya, Leonel, Ansstas, George, Chen, David Y.
Publicado 2022

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation

por Khaddour, Karam, Dowling, Joshua, Huang, Jiayi, Council, Martha, Chen, David, Cornelius, Lynn, Johanns, Tanner, Dahiya, Sonika, Ansstas, George
Publicado 2020

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mut...

por Khaddour, Karam, Dowling, Joshua, Huang, Jiayi, Council, Martha, Chen, David, Cornelius, Lynn, Johanns, Tanner, Dahiya, Sonika, Ansstas, George
Publicado 2023

Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis

por Jaeger, Zachary J., Raval, Neel S., Maverakis, Natalia K. A., Chen, David Y., Ansstas, George, Hardi, Angela, Cornelius, Lynn A.
Publicado 2023

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology

por Akinjiyan, Favour A., Morecroft, Renee, Phillipps, Jordan, Adeyelu, Tolulope, Elliott, Andrew, Park, Soo J., Butt, Omar H., Zhou, Alice Y., Ansstas, George
Publicado 2023

Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab

por Hwang, Helen, Huang, Jiayi, Khaddour, Karam, Butt, Omar H, Ansstas, George, Chen, Jie, Katumba, Ruth GN, Kim, Albert H, Leuthardt, Eric C, Campian, Jian L
Publicado 2022

BRAF mutations may identify a clinically distinct subset of glioblastoma

por McNulty, Samantha N., Schwetye, Katherine E., Ferguson, Cole, Storer, Chad E., Ansstas, George, Kim, Albert H., Gutmann, David H., Rubin, Joshua B., Head, Richard D., Dahiya, Sonika
Publicado 2021

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours

por Kasi, Pashtoon Murtaza, Chakrabarti, Sakti, Sawyer, Sarah, Krainock, Michael, Poklepovic, Andrew, Ansstas, George, Maninder, Minu, Malhotra, Meenakshi, Ensor, Joe, Gao, Ling, Eroglu, Zeynep, Ellers, Sascha, Billings, Paul, Rodriguez, Angel, Aleshin, Alexey
Publicado 2022